Summit Therapeutics Stock Jumps on Positive Overall Survival Data for Lung Cancer Drug

Shares of Summit Therapeutics (NASDAQ: SMMT) rallied more than 11% in morning trading after its partner, Akeso Inc., announced positive results from a late-stage clinical trial for the cancer immunotherapy ivonescimab.

Pivotal Trial Meets Survival Endpoint

Akeso reported that the Phase III HARMONi-2 study met its key secondary endpoint for overall survival (OS) at a prespecified interim analysis. The trial evaluated ivonescimab as a monotherapy against pembrolizumab (Merck's Keytruda) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express the protein PD-L1.

The results showed that ivonescimab delivered a statistically significant survival advantage over pembrolizumab. This follows a previous announcement that the China-based, 398-patient trial had also demonstrated a meaningful benefit in progression-free survival (PFS), reinforcing the drug's potential in a highly competitive area of oncology.

Market Reaction and Analyst Outlook

The positive data spurred a significant stock move, with SMMT shares climbing 11.6% in the morning session. The move was amplified by a constructive broader market, with major indices like the S&P 500 posting gains.

Ad

Analyst reactions were mixed, highlighting different perspectives on the data:

• H.C. Wainwright reiterated a Neutral rating, expressing some caution that the HARMONi-2 study was conducted exclusively in China.
• Cantor Fitzgerald maintained its Overweight stance on the stock.
• The broader Wall Street consensus remains constructive, with ten buy ratings against seven holds and no sell ratings, according to the source.

Awaiting Key FDA Decision

This positive survival data arrives at a critical time for Summit. The company faces a U.S. Food and Drug Administration (FDA) review date for ivonescimab in this lung cancer indication in mid-November.

Each positive data readout is seen as incrementally important for investors as it strengthens the drug's clinical profile ahead of this key regulatory milestone. A potential approval would position Summit to compete in one of the largest markets in cancer treatment.